High demand of popular obesity drug Saxenda; may be going to "wrong" patients

26 November 2022 - Since April of this year there has been a high demand for the obesity drug Saxenda, but ...

Read more →

Amryt receives reimbursement approval from the Dutch Ministry of Health for Myalepta (metreleptin)

17 October 2022 - Amryt receives reimbursement approval from the Dutch Ministry of Health for Myalepta (metreleptin). ...

Read more →

Doctors, patients protest at plans to cap medicine prices

23 September 2022 - Doctors, pharmacists and patients organisations are angry about government plans to cut spending on medicine, which ...

Read more →

Key considerations in the health technology assessment of advanced therapy medicinal products in Scotland, The Netherlands and England

8 March 2022 - Advanced therapy medicinal products are highly innovative therapies. Their costs and uncertain value claims have raised concerns ...

Read more →

Dutch health insurance: what changes in 2022?

11 November 2021 - The Dutch healthcare institute Zorginstituut Nederland is going to increase its monitoring of treatment to better ...

Read more →

Patients in the Netherlands wait 1.5 years for access to new medicines

2 September 2021 - Patients in the Netherlands have to wait an average of 510 days for access to a new ...

Read more →

Hansa Biopharma announces reimbursement in the Netherlands of Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients

2 August 2021 - Idefiris (imlifidase) for enabling kidney transplantation in highly sensitised patients is now reimbursable and available for use ...

Read more →

Dutch advisory group says Zolgensma shouldn’t be covered unless Novartis halves price

10 May 2021 - In a challenge to Novartis, a Dutch advisory body has recommended that the government not cover ...

Read more →

World’s most expensive drug may not be covered by Dutch insurance

7 May 2021 - A drug to treat a rare muscle disease which affects some 20 children in the Netherlands ...

Read more →

Ineffective treatments to be removed from basic health insurance package

5 October 2020 - Treatments that have not been proven effective will be removed from the Netherlands' basic health insurance package, ...

Read more →

Did a pharma trade group try to sabotage a Dutch government report on compulsory licensing?

7 July 2020 - Dutch government commission on compulsory licensing was nearly sabotaged last month after one of its members ...

Read more →

Celltrion’s Remsima SC launches in Netherlands

7 May 2020 - Subcutaneous rheumatoid arthritis treatment Remsima SC launched in the Netherlands, its third European market, Celltrion Healthcare ...

Read more →

Five pillars for societal perspective

31 January 2020 - In economic evaluation, the healthcare perspective has gradually given way to use of the societal perspective, as ...

Read more →

DIY drugs: should hospitals make their own medicine?

15 October 2019 - If pharmaceutical companies rapidly inflate the price of their products, is there an alternative? One Dutch chemist ...

Read more →

Dutch experience demonstrates effective benchmarking of biosimilar use in health systems

31 August 2019 - As medicines become more numerous and often more expensive, health care professionals seek new ways to understand ...

Read more →